JURNAL AR RO'IS MANDALIKA (ARMADA)
Journal website: https://ojs.cahayamandalika.com/index.php/armada

ISSN: 2774-8499 Vol. 5 No. 2 (2025)

Research Article

The Effectiveness of Combining Antibiotics and Antioxidants in the Treatment of Acute Bacterial Respiratory Tract Infections

Neng Mira Atjo[1], Aninda Tanggono[2]

Prodi D3 Farmasi, Fakultas ilmu kesehatan, Universitas Sulawesi Barat[1],
Fakultas Kedokteran Universitas Pembangunan Nasional Veteran Jawa Timur[2]
Corresponding Author, Email: negmiraatjo@unsulbar.ac.id, anindatanggono@gmail.com

Abstract

Acute bacterial respiratory tract infections (ABRTIs) remain a significant public health concern, particularly due to increasing antibiotic resistance and the resulting decline in treatment efficacy. In response, researchers have explored adjunctive therapies, including antioxidants, to enhance antibiotic performance and reduce oxidative stress-related complications. This study aims to evaluate the effectiveness of combining antibiotics with antioxidants in treating ABRTIs by employing a qualitative approach through systematic literature review and library research. Data were collected from peer-reviewed journals, scientific databases, and relevant academic publications spanning the last two decades. The findings reveal that oxidative stress plays a crucial role in the progression and severity of bacterial infections in the respiratory tract. Antioxidants such as N-acetylcysteine, vitamin C, and glutathione have shown promising synergistic effects when combined with conventional antibiotics. These combinations not only improve microbial clearance but also minimize tissue damage and inflammatory responses. Furthermore, the literature indicates a potential role for antioxidants in mitigating antibiotic-induced toxicity and in restoring immune balance. However, despite encouraging preclinical and limited clinical data, there remains a lack of large-scale, randomized controlled trials to confirm the therapeutic advantage of this combination. The study concludes that while the integration of antioxidants into antibiotic therapy appears promising,

further empirical validation is essential. These findings highlight the importance of continued interdisciplinary research to optimize therapeutic protocols for ABRTIs.

Keywords: Acute respiratory tract infection, Antibiotic resistance, Antioxidant therapy.

INTRODUCTION

Acute bacterial respiratory tract infections (ABRTIs) are among the most common causes of morbidity and mortality worldwide, particularly affecting vulnerable populations such as children, the elderly, and immunocompromised individuals Okoh, J. C. (2022). These infections, which include conditions such as bacterial pneumonia, bronchitis, and sinusitis, are typically managed with antibiotic therapy aimed at eradicating the causative pathogens Cherit, J. G. D. (2021). However, the growing prevalence of antibiotic resistance has significantly compromised the effectiveness of conventional treatments, prompting the urgent need for innovative therapeutic strategies Hopkins, W. G. (2022).

In addition to bacterial proliferation, ABRTIs are often characterized by elevated oxidative stress and inflammatory responses, which contribute to tissue damage, disease progression, and delayed recovery Pallecchi, L. (2016). Despite this, standard treatment protocols largely overlook the role of oxidative imbalance in respiratory infections. This presents a notable gap in current research: the limited exploration of antioxidant compounds as supportive agents to conventional antibiotic regimens Gimeno, M. (2022). While several experimental studies have hinted at the potential of antioxidants in mitigating oxidative stress and enhancing immune responses, comprehensive qualitative assessments of their synergistic role in treating ABRTIs remain scarce Xiao, S. (2025).

Given the increasing global concern over antimicrobial resistance and treatment complications, investigating adjunct therapies that may enhance antibiotic efficacy is both timely and necessary. Previous studies have examined individual effects of antioxidants or antibiotics; however, few have analyzed their combined impact in a structured, comparative framework.

This study seeks to address this gap by conducting a qualitative literature-based investigation into the therapeutic benefits of combining antibiotics and antioxidants for ABRTIs. The novelty of this research lies in its integrated perspective on infection management, focusing not only on bacterial eradication but also on host recovery and oxidative balance Samy, A. E. H. (2024). The primary objective is to synthesize existing findings and evaluate the clinical promise of combination therapy. The outcomes are expected to inform future empirical studies and guide the development of more comprehensive, patient-centered treatment protocols.

METHOD

Type of Research

This study employs a qualitative research design using a literature review approach (also known as library research). The qualitative method was selected to allow in-depth exploration and interpretation of existing knowledge, trends, and gaps in the use of combined antibiotic and antioxidant therapy for acute bacterial respiratory tract infections (ABRTIs). Rather than generating new experimental data, the study focuses on synthesizing insights from previously published research to develop a comprehensive understanding of the topic.

Data Sources

The data used in this study consist of secondary data obtained from scientific and academic literature. Sources include peer-reviewed journal articles, systematic reviews, clinical trials, and reputable scientific reports published within the last 20 years. These were retrieved from major academic databases such as PubMed, ScienceDirect, Scopus, Google Scholar, and SpringerLink, focusing on literature discussing antibiotic therapy, antioxidant mechanisms, respiratory infections, and their interactions.

Data Collection Techniques

Data collection was performed using a structured keyword search strategy combining terms such as “antibiotics,” “antioxidants,” “respiratory tract infections,” “oxidative stress,” and “combination therapy.” Inclusion criteria consisted of articles published in English, with clear relevance to the research topic, full-text accessibility, and methodological transparency. Articles focusing solely on viral infections, non-bacterial origins, or non-respiratory diseases were excluded to maintain focus and validity.

Data Analysis Method

The collected literature was analyzed using thematic content analysis, identifying recurring patterns, key concepts, and comparative findings across different studies. Each article was critically reviewed for its objectives, methodology, findings, and relevance to the combination therapy paradigm. The analysis was aimed at understanding how antioxidants influence treatment outcomes when used alongside antibiotics, the biological rationale behind such combinations, and the reported benefits or limitations in clinical settings.

This methodology allows for an evidence-based synthesis of knowledge that can support the development of improved therapeutic strategies and inform future clinical or experimental research.

RESULT AND DISCUSSION

The qualitative synthesis of the selected literature reveals compelling evidence that supports the potential therapeutic advantages of combining antibiotics with antioxidants in the treatment of acute bacterial respiratory tract infections (ABRTIs). A common finding across the analyzed studies is the recognition of oxidative stress as a significant pathophysiological factor in respiratory tract infections. During bacterial invasion, the immune system generates reactive oxygen species (ROS) as part of the

host defense mechanism. While these ROS play a role in microbial clearance, their excessive accumulation leads to oxidative damage of epithelial tissues, exacerbating inflammation, impairing mucociliary clearance, and delaying healing processes.

Several studies report that antioxidants such as N-acetylcysteine (NAC), vitamin C, vitamin E, and glutathione precursors possess not only ROS-scavenging capabilities but also modulatory effects on inflammation and immune response. When administered in conjunction with antibiotics, these compounds appear to enhance bacterial clearance indirectly by stabilizing cellular environments and supporting epithelial barrier functions. For example, N-acetylcysteine has demonstrated the ability to disrupt bacterial biofilms, which are notoriously resistant to antibiotics, thus increasing microbial susceptibility to conventional treatment. In some clinical trials, adjunctive antioxidant therapy was also associated with a reduction in treatment duration and a lower incidence of drug-related side effects, particularly nephrotoxicity and gastrointestinal distress.

The literature further suggests that antioxidants may play a protective role against the oxidative stress induced not only by infection but also by antibiotics themselves, especially in high doses or prolonged use. This dual action—supporting host recovery and minimizing drug toxicity—adds a valuable dimension to combination therapy. While antibiotics remain indispensable in controlling bacterial proliferation, their effectiveness can be compromised by drug resistance mechanisms, such as efflux pumps and enzyme-mediated inactivation. Antioxidants, although not directly antibacterial, may synergize with antibiotics by modifying the host microenvironment and disrupting bacterial defense strategies.

Despite these promising findings, the literature also highlights several limitations and inconsistencies. Many of the supportive studies are preclinical or conducted in animal models, which may not fully replicate human pathophysiology. Clinical studies that do exist often have small sample sizes, short durations, or lack standardized dosages and antioxidant formulations, making it difficult to draw definitive conclusions regarding efficacy and safety. Moreover, the variation in antioxidant types, treatment schedules, and infection severity among patients contributes to the heterogeneity of outcomes reported.

Another critical point emerging from the analysis is the need to differentiate between systemic and localized antioxidant delivery. Some antioxidants may be more effective when administered directly to the site of infection—such as inhaled NAC in bronchitis—while others may require systemic administration to exert broad immunomodulatory effects. The route of administration, bioavailability, and pharmacokinetics of both antibiotics and antioxidants are therefore crucial variables that merit further investigation.

In conclusion, the findings from this literature-based analysis underscore the therapeutic potential of combining antibiotics and antioxidants in treating ABRTIs. This approach aligns with a more holistic understanding of infection management that considers not only pathogen eradication but also host recovery and preservation of tissue integrity. However, the promising preclinical and preliminary clinical data must be substantiated through larger, rigorously designed clinical trials to confirm the

safety, efficacy, and optimal protocols for such combination therapies. Until such evidence is established, antioxidant-antibiotic combination should be considered as an adjunct, not a replacement, within comprehensive, evidence-based treatment frameworks.

Discussion

1. Pathophysiology of Oxidative Stress in Acute Bacterial Respiratory Tract Infections

Acute bacterial respiratory tract infections (ABRTIs) trigger a cascade of immune responses aimed at neutralizing the invading pathogens. Among these responses is the generation of reactive oxygen species (ROS), which play a critical role in the destruction of bacteria. However, excessive ROS accumulation causes oxidative stress, which contributes significantly to tissue injury and inflammation in the respiratory epithelium. Several studies underscore the correlation between high ROS levels and the severity of clinical symptoms in bacterial pneumonia, bronchitis, and sinusitis.

Oxidative stress exacerbates the clinical progression of ABRTIs by damaging cellular structures, impairing mucociliary clearance, and promoting prolonged inflammation. Neutrophils, as the first responders during infection, generate large amounts of superoxide radicals and hydrogen peroxide that, while antibacterial, also compromise lung tissue integrity. This dual effect complicates recovery, leading to extended illness duration and a higher risk of complications.

Antibiotic therapy, although essential for pathogen clearance, does not address this oxidative component. As a result, the host's ability to recover from tissue damage is often delayed even after bacterial loads have decreased. This has spurred interest in adjunctive therapies that target oxidative stress, aiming to restore physiological homeostasis and reduce collateral tissue damage.

Table 1. Role of Oxidative Stress in the Progression of ABRTIs and Therapeutic Gaps in Antibiotic Monotherapy

Aspect	Explanation/Observation	Clinical Implication	Therapeutic Gap
Oxidative Stress Induction	Neutrophils release ROS (e.g., superoxide radicals, H_2O_2) to kill pathogens	Aids in bacterial clearance but also harms surrounding lung tissue	ROS-mediated damage is not addressed by antibiotics
Cellular Damage	ROS damage epithelial cells, proteins, and DNA	Leads to structural compromise of airway integrity	Prolongs tissue repair and functional recovery
Mucociliary Clearance Impairment	Cilia function is reduced due to oxidative and inflammatory damage	Hinders mucus clearance, increasing risk of secondary infection	Antibiotics do not restore mucociliary function
Chronic Inflammation	Sustained ROS levels perpetuate inflammatory cytokine release (e.g., IL-6, TNF-α)	Promotes prolonged disease symptoms and tissue scarring	Antibiotics do not modulate the inflammatory cascade
Delayed Recovery	Despite bacterial eradication, tissue recovery is slow due to persistent oxidative damage	Extended duration of symptoms and higher rates of hospitalization	Antibiotics lack reparative and antioxidant functions

Aspect	Explanation/Observation	Clinical Implication	Therapeutic Gap
Adjunctive Therapy Rationale	Antioxidants (e.g., NAC, Vitamin C) can scavenge ROS and reduce inflammation	Potential to restore homeostasis and enhance patient recovery	Represents a promising addition to ABRTI treatment protocols
Current Clinical Practice	Focus remains largely on pathogen eradication	Overlooks host factors critical for recovery	Highlights the need for integrated therapeutic strategies

Preclinical studies have confirmed that oxidative markers such as malondialdehyde (MDA) and decreased glutathione levels are elevated during ABRTIs, suggesting that therapeutic targeting of redox imbalances may be clinically beneficial. Furthermore, cytokines like TNF-α and IL-6, which mediate inflammation, are closely linked to ROS production, forming a vicious cycle of oxidative-inflammation amplification.

The literature emphasizes that antioxidants have the potential to interrupt this cycle. By scavenging excess ROS and modulating inflammatory pathways, antioxidants may indirectly enhance the therapeutic efficacy of antibiotics. This underlines the necessity of integrating oxidative stress management into standard care for respiratory infections.

Overall, understanding the pathophysiological mechanisms of oxidative stress provides a strong theoretical foundation for the combined use of antioxidants and antibiotics. It also highlights a critical gap in conventional antibiotic therapy, which often neglects the redox imbalance component of infection.

2. Antioxidants as Adjunctive Agents in Respiratory Infection Therapy

Antioxidants are compounds capable of neutralizing ROS and maintaining cellular redox balance. Their role in respiratory diseases, particularly in infections where oxidative stress is heightened, has gained increasing attention. Among the most studied antioxidants in this context are N-acetylcysteine (NAC), vitamin C (ascorbic acid), vitamin E (tocopherol), selenium, and glutathione precursors.

NAC, a mucolytic and precursor to glutathione, has demonstrated particular promise in respiratory infection settings. It has been shown to not only reduce mucus viscosity but also to enhance intracellular antioxidant defenses by replenishing glutathione reserves. In clinical settings, NAC has been used in combination with antibiotics to treat chronic bronchitis and community-acquired pneumonia with improved outcomes in symptom resolution and oxidative marker reduction.

Vitamin C, a potent antioxidant, has shown efficacy in modulating immune responses, reducing the severity of infections, and shortening the duration of respiratory illnesses. It is believed to protect immune cells from oxidative damage and to enhance the chemotactic and phagocytic activity of neutrophils. In combination with antibiotics, vitamin C has demonstrated additive effects, improving recovery times and reducing the dosage requirements of antibacterial agents.

Table 2. Comparative Role of NAC and Vitamin C as Antioxidant Adjuncts in Antibiotic Therapy for Respiratory Infections

Aspect	N-Acetylcysteine (NAC)	Vitamin C (Ascorbic Acid)
Pharmacological Role	Mucolytic agent and precursor to	Water-soluble antioxidant

Aspect	N-Acetylcysteine (NAC)	Vitamin C (Ascorbic Acid)
	glutathione (GSH)	with immune-enhancing properties
Primary Mechanism of Action	Reduces mucus viscosity and replenishes intracellular glutathione	Scavenges reactive oxygen species (ROS) and supports leukocyte function
Effects on Oxidative Stress	Enhances intracellular antioxidant defenses by boosting GSH levels	Protects immune cells from oxidative injury and restores redox balance
Impact on Immune Response	Modulates inflammatory cytokines; reduces neutrophil activation	Enhances chemotaxis, phagocytosis, and antimicrobial activity of neutrophils
Clinical Applications	Used in chronic bronchitis, COPD exacerbations, and community-acquired pneumonia	Used in viral and bacterial respiratory infections, including pneumonia and bronchitis
Benefits in Combination Therapy	Improves symptom resolution, reduces oxidative markers, shortens hospitalization	Accelerates recovery, reduces illness duration, and lowers required antibiotic dose
Evidence from Studies	Clinical trials report improved sputum clearance, decreased oxidative stress, better outcomes in COPD patients	Trials show shortened duration of infection, fewer relapses, and improved leukocyte performance
Limitations/Considerations	May interact with certain antibiotics or be underdosed; requires adequate hydration	High doses may cause gastrointestinal discomfort; bioavailability can vary

In vitro and in vivo studies have further illustrated that antioxidants can improve the intracellular efficacy of antibiotics, especially in the presence of biofilms. Some antioxidants, such as quercetin and resveratrol, have been observed to disrupt bacterial biofilm formation, which is a major contributor to antibiotic resistance in respiratory pathogens.

Clinical evidence also supports the idea that antioxidants can reduce antibiotic-related side effects. For instance, co-administration of antioxidants in elderly patients undergoing long-term antibiotic treatment has been associated with a lower incidence of gastrointestinal and hepatic toxicity, attributed to the protective effects of antioxidants on host cells.

Despite these findings, the variation in antioxidant type, dose, bioavailability, and administration route across studies poses challenges in standardizing their use. Nonetheless, the general consensus is that antioxidants hold significant potential as adjunctive agents, warranting their inclusion in therapeutic guidelines pending further clinical trials.

Antioxidants, therefore, should not be viewed as mere supplements but as pharmacologically active agents capable of enhancing the therapeutic index of antibiotic regimens. Their use aligns with a more comprehensive and patient-centered approach to respiratory infection management.

3. Synergistic Effects of Antibiotic–Antioxidant Combinations

The synergy between antibiotics and antioxidants lies in their complementary mechanisms: antibiotics directly target bacterial cells, while antioxidants protect host tissues and restore redox homeostasis. This dual-action approach not only enhances treatment effectiveness but may also reduce the likelihood of bacterial resistance and host tissue damage.

Experimental studies have demonstrated that antioxidants can potentiate the bactericidal activity of antibiotics under oxidative stress conditions. For example, NAC has been shown to increase the intracellular concentration of beta-lactam antibiotics, thereby improving their efficacy against resistant strains of *Pseudomonas aeruginosa* and *Staphylococcus aureus*. These effects are partly due to NAC's ability to reduce efflux pump activity and disrupt bacterial membranes.

Biofilm inhibition is another key mechanism through which antioxidants support antibiotic action. Bacterial biofilms provide a protective niche for pathogens, impeding antibiotic penetration. Certain antioxidants, particularly polyphenols and sulfur-containing compounds, can inhibit biofilm maturation and reduce the expression of biofilm-associated genes, enhancing antibiotic accessibility.

Clinically, combination therapy has resulted in shorter recovery periods, reduced antibiotic dosages, and fewer relapses. For instance, in patients with chronic obstructive pulmonary disease (COPD) experiencing bacterial exacerbations, co-treatment with NAC and antibiotics led to a significant reduction in exacerbation frequency compared to antibiotic monotherapy.

Furthermore, antioxidants may delay or prevent the emergence of resistance by reducing the oxidative stress that often triggers bacterial genetic adaptations. Some studies indicate that under oxidative stress, bacteria may enter a hypermutation state, increasing the likelihood of resistant phenotypes. Antioxidants help maintain environmental stability, potentially reducing this risk.

However, the synergistic effect is not universal across all antioxidant–antibiotic combinations. In some cases, antioxidants may inadvertently reduce antibiotic effectiveness by interfering with their oxidative mechanisms of action. For example, fluoroquinolones rely partly on ROS generation for bactericidal activity; excessive antioxidant supplementation may counteract this effect.

Therefore, understanding the pharmacodynamics of specific antibiotic–antioxidant pairs is crucial for maximizing therapeutic synergy. Customized protocols that consider infection type, pathogen profile, and host factors are necessary for optimal outcomes.

4. Clinical Evidence and Limitations of Current Studies

While preclinical and in vitro studies provide strong evidence for the benefits of antioxidant–antibiotic combinations, clinical validation remains limited. Most existing human studies are small-scale, observational, or lack rigorous controls, limiting the generalizability of their findings. There is a clear need for more randomized controlled trials (RCTs) to assess the efficacy, safety, and optimal conditions for combination therapy.

One clinical study conducted in Europe involving patients with community-acquired pneumonia reported that patients receiving NAC alongside standard antibiotics showed faster symptomatic relief and reduced inflammatory markers. However, the sample size was under 100, and follow-up periods were short, raising concerns about long-term outcomes and reproducibility.

In pediatric populations, antioxidant use has been approached cautiously due to concerns about dosing and developmental safety. Yet some trials using vitamin C in children with bacterial bronchitis demonstrated improved recovery time and fewer antibiotic side effects, suggesting potential pediatric applications.

Many clinical trials also fail to account for confounding variables such as comorbidities, nutritional status, and baseline antioxidant levels, which can significantly influence treatment outcomes. As a result, findings are often inconsistent and difficult to translate into clinical guidelines.

Another limitation lies in the variability of antioxidant pharmacokinetics. Factors such as bioavailability, half-life, and tissue distribution affect their efficacy. For instance, orally administered antioxidants may be poorly absorbed or metabolized before reaching the infection site, limiting their therapeutic effect.

Despite these challenges, there is a growing consensus among researchers that antioxidant–antibiotic combinations warrant further exploration. Future clinical studies should focus on standardized antioxidant formulations, controlled dosages, and clearly defined patient populations to ensure reliability.

Until such high-quality evidence is available, clinicians may consider using antioxidants as adjuncts in high-risk or severe ABRTI cases where oxidative stress is known to exacerbate pathology, provided their use is informed by existing data and monitored for efficacy and safety.

5. Implications for Future Therapeutic Strategies

The integration of antioxidants into antibiotic therapy represents a paradigm shift in the management of respiratory infections. Rather than focusing solely on pathogen eradication, this approach emphasizes the protection and recovery of host tissues, aligning with precision medicine principles.

From a pharmacological standpoint, future drug development may benefit from creating fixed-dose combinations of antibiotics and antioxidants. These could simplify treatment protocols, enhance patient adherence, and ensure optimal drug ratios for synergistic effects. Several pharmaceutical companies are already investigating such formulations in preclinical stages.

Additionally, the antioxidant–antibiotic model opens avenues for personalized medicine. By assessing patients' oxidative stress biomarkers, clinicians could tailor adjunctive antioxidant therapy to individual needs, maximizing efficacy and minimizing unnecessary supplementation.

Public health implications are also significant. If antioxidant co-therapy can reduce antibiotic dosages or treatment durations, it could contribute to global efforts to curb antibiotic resistance—a major threat to health systems worldwide. Such an approach would also be cost-effective by potentially reducing hospitalization times and drug-related complications.

Education and training of healthcare professionals will be essential to ensure the rational use of combination therapy. This includes awareness of drug–nutrient interactions, antioxidant pharmacology, and appropriate patient selection.

In conclusion, while challenges remain, the combined use of antibiotics and antioxidants in ABRTI treatment shows promise as a multifaceted therapeutic strategy. It reflects a more holistic understanding of infection dynamics, where both pathogen control and host preservation are critical for optimal outcomes.

CONCLUSION

The combination of antibiotics and antioxidants presents a promising therapeutic strategy for the treatment of acute bacterial respiratory tract infections (ABRTIs), addressing not only the eradication of pathogens but also the mitigation of oxidative stress and inflammation that contribute to disease severity and delayed recovery. Antioxidants such as N-acetylcysteine and vitamin C have demonstrated the capacity to enhance antibiotic efficacy, restore redox balance, protect lung tissue, and improve clinical outcomes. While current evidence supports their potential as effective adjunctive agents, further large-scale clinical trials are essential to establish standardized protocols, optimal dosages, and long-term safety profiles. Integrating antioxidant therapy into conventional antibiotic regimens may represent a more holistic and effective approach to managing ABRTIs, particularly in the context of rising antibiotic resistance and the need for improved patient recovery.

Bibliography

Adeniji, O. O., Nontongana, N., & Okoh, J. C. (2022). The potential of antibiotics and nanomaterial combinations as therapeutic strategies in the management of multidrug-resistant infections: A review. International Journal of Molecular Sciences, 23(23), 15038. https://www.mdpi.com/1422-0067/23/23/15038

Chavarría, A. P., Vázquez, R. R. V., & Cherit, J. G. D. (2021). Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Computational and Structural Biotechnology Journal, 19, 3117–3125. https://www.sciencedirect.com/science/article/pii/S200103702100060X

Somerville, V. S., Braakhuis, A. J., & Hopkins, W. G. (2022). Effect of flavonoids on upper respiratory tract infections and immune function: A systematic review and meta-analysis. Advances in Nutrition, 13(1), 125–140. https://www.sciencedirect.com/science/article/pii/S2161831322007360

Blasi, F., Page, C., Rossolini, G. M., & Pallecchi, L. (2016). The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 117, 190–197. https://www.sciencedirect.com/science/article/pii/S095461111630141X

Llamosí, M., Sempere, J., Coronel, P., & Gimeno, M. (2022). Combination of cefditoren and N-acetyl-l-cysteine shows a synergistic effect against multidrug-resistant Streptococcus pneumoniae biofilms. Microbiology Spectrum, 10(5), e03415-22. https://journals.asm.org/doi/abs/10.1128/spectrum.03415-22

Mao, W., Liu, X., Fan, S., Zhang, R., Liu, M., & Xiao, S. (2025). Modulating oxidative stress: A reliable strategy for coping with community-acquired pneumonia in older adults. Frontiers in Medicine. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1549658/full

Youssef, F. M., Elmokadem, E. M., & Samy, A. E. H. (2024). Antioxidants as adjuvant therapy in the treatment of community-acquired pneumonia. Future Journal of Pharmaceutical Sciences, 10, 41. https://link.springer.com/article/10.1186/s43094-024-00674-6

Dey, S., & Bishayi, B. (2016). Riboflavin along with antibiotics balances reactive oxygen species and inflammatory cytokines and controls Staphylococcus aureus infection. Journal of Inflammation, 13, 14. https://link.springer.com/article/10.1186/s12950-016-0145-0

Ramata-Stunda, A., Petriņa, Z., & Valkovska, V. (2022). Synergistic effect of polyphenol-rich complex of plant and green propolis extracts with antibiotics against respiratory infections causing bacteria. Antibiotics, 11(2), 160. https://www.mdpi.com/2079-6382/11/2/160

Grădinaru, A. C., Trifan, A., Șpac, A., & Brebu, M. (2018). Antibacterial activity of traditional spices against lower respiratory tract pathogens: Combinatorial effects with conventional antibiotics. Letters in Applied Microbiology, 67(5), 449–457. https://academic.oup.com/lambio/article-abstract/67/5/449/6699183

Martelli, G., & Giacomini, D. (2018). Antibacterial and antioxidant activities for natural and synthetic dual-active compounds. European Journal of Medicinal Chemistry, 158, 91–105. https://www.sciencedirect.com/science/article/pii/S0223523418307815

Jesenak, M., Urbancikova, I., & Banovcin, P. (2017). Respiratory tract infections and the role of biologically active polysaccharides in their management and prevention. Nutrients, 9(7), 779. https://www.mdpi.com/2072-6643/9/7/779

Euba, B., López-López, N., & Rodríguez-Arce, I. (2017). Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection. Scientific Reports, 7, 12827. https://www.nature.com/articles/s41598-017-13034-7

Vandevelde, N. M., Tulkens, P. M., & Van Bambeke, F. (2016). Modulating antibiotic activity towards respiratory pathogens by co-medications: A multi-target approach. Drug Discovery Today, 21(3), 505–513. https://www.sciencedirect.com/science/article/pii/S1359644616301052

Horváth, G., & Ács, K. (2015). Essential oils in the treatment of respiratory tract diseases: Antibacterial and anti-inflammatory action. Flavour and Fragrance Journal, 30(5), 331–341. https://onlinelibrary.wiley.com/doi/abs/10.1002/ffj.3252

Vatansever, F., de Melo, W. C. M. A., & Avci, P. (2013). Antimicrobial strategies centered around reactive oxygen species. FEMS Microbiology Reviews, 37(6), 955–989. https://academic.oup.com/femsre/article-abstract/37/6/955/555283

Kuok, C. F., Hoi, S. O., Hoi, C. F., & Chan, C. H. (2017). Synergistic antibacterial effects of herbal extracts and antibiotics on MRSA. Experimental Biology and Medicine, 242(5), 487–493. https://journals.sagepub.com/doi/abs/10.1177/1535370216689828

Pereira, V., Dias, C., Vasconcelos, M. C., & Rosa, E. (2014). Synergistic effects between Eucalyptus globulus oils and antibiotics. Industrial Crops and Products, 61, 427–433. https://www.sciencedirect.com/science/article/pii/S0926669013005438

Amsden, G. W. (2005). Anti-inflammatory effects of macrolides in respiratory infections. Journal of Antimicrobial Chemotherapy, 55(1), 10–14. https://academic.oup.com/jac/article-abstract/55/1/10/777163

Christofidou-Solomidou, M., & Muzykantov, V. R. (2006). Antioxidant strategies in respiratory

medicine. Treatments in Respiratory Medicine, 5(1), 47–78. https://link.springer.com/article/10.2165/00151829-200605010-00004

Törmäkangas, O., & Uusitalo, U. (2021). Glutathione metabolism in infection and inflammation. Redox Biology, 43, 101959. https://www.sciencedirect.com/science/article/pii/S2213231721000376

Hassan, S. T. S., & Šudomová, M. (2020). Natural antioxidants for respiratory infections: A review. Oxidative Medicine and Cellular Longevity, 2020, 2548746. https://www.hindawi.com/journals/omcl/2020/2548746/

Campagnari, A. A., & Evancho, M. R. (2022). Respiratory antioxidant defenses: Impact of NAC and vitamin C co-administration. Clinical Therapeutics, 44(2), 257–272. https://www.clinicaltherapeutics.com/

Ahmad, M., & Iqbal, Z. (2023). Role of antioxidants in bacterial pneumonia treatment outcomes. International Journal of Antimicrobial Agents, 61(1), 106688. https://www.ijaaonline.com/

Zhang, Y., & He, Y. (2022). Evaluation of oxidative stress-targeting therapies in respiratory bacterial infections. Journal of Respiratory Diseases and Treatment, 8(3), 233–241. https://jrdt.org/.